Choose the brand aligned with your industry so we can best serve your needs.
For researchers, scientists, and technical professionals: Your one-stop shop for the complete range of laboratory, production, and safety products and services.
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
Chemical. CAS 426-65-3. Formula C5H5F5O2. MW 192.08. Building block for synthesis. Perfluoroalkyl carboxylate esters undergo Wittig reactions with phosphorus leading to 1-perfluoroalkyl enol ethers, which are useful precursors of various fluorinated derivatives.
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
Also available in 1 mg 2 mg 5 mg 25 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration X-396 binds to and inhibits ALK kinase ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. purity: 98%
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
LMP2A (426-434) is an HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). It can trigger an immune response in individuals expressing various HLA-A*02 subtypes and induces a strong IFN-γ secretion response, leading to a high proportion of CD8+ IFN-γ+ T cells. It induces specific CTLs that effectively kill target cells expressing LMP2A.
Suitable for studying EBV-related malignant tumors, such as Hodgkin's disease and nasopharyngeal carcinoma.
Induces IFN-γ secreting cells at a frequency of 80.6 SFC/5x10⁴ CD8+ T cells (at 20 μg/mL for 24 h).
Significantly increases the proportion of CD8+IFN-γ+ cells after two weeks of stimulation (at 20 μg/mL).
Specific CTLs effectively kill peptide-pulsed T2 cells and 293T-LMP2A cells (at 20 μg/mL for 4 h).
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More